Who are COV155's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atomoxetine (ATO), SPN-812 (600mg, QD), Strattera (atomoxetine), atomoxetine (or placebo), Atomoxetine (Strattera), AXS-14 (Esreboxetine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cov155.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

COV155 — Competitive Intelligence Brief

COV155 (COV155) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine reuptake inhibitor (NRI). Area: Neurology / Psychiatry.

phase 3 Norepinephrine reuptake inhibitor (NRI) Norepinephrine transporter (NET) Neurology / Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

COV155 (COV155) — Mallinckrodt. COV155 is a selective norepinephrine reuptake inhibitor that increases norepinephrine levels in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
COV155 TARGET	COV155	Mallinckrodt	phase 3	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
Atomoxetine (ATO)	Atomoxetine (ATO)	Janssen Research & Development, LLC	marketed	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
SPN-812 (600mg, QD)	SPN-812 (600mg, QD)	Supernus Pharmaceuticals, Inc.	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
Strattera (atomoxetine)	Strattera (atomoxetine)	Massachusetts General Hospital	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
atomoxetine (or placebo)	atomoxetine (or placebo)	University of Arizona	marketed	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
Atomoxetine (Strattera)	Atomoxetine (Strattera)	University of Pittsburgh	marketed	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
AXS-14 (Esreboxetine)	AXS-14 (Esreboxetine)	Axsome Therapeutics, Inc.	phase 3	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine reuptake inhibitor (NRI) class)

Axsome Therapeutics, Inc. · 2 drugs in this class
Janssen Research & Development, LLC · 1 drug in this class
Mallinckrodt · 1 drug in this class
University of Arizona · 1 drug in this class
University of Pittsburgh · 1 drug in this class
Vrije Universiteit Brussel · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COV155 — Competitive Intelligence Brief. https://druglandscape.com/ci/cov155. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab